Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CTLA4-Ig: a novel immunosuppressive agent.

N Najafian1, M H Sayegh

  • 1Brigham and Women 's Hospital, Renal Division, Immunogenetics and Transplantation, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. nnajafian@rics.bwh.harvard.edu

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.

Transplantation proceedings·2017
Same author

Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

TIM-1 signaling is required for maintenance and induction of regulatory B cells.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

T Helper Cells Fate Mapping by Co-stimulatory Molecules and its Functions in Allograft Rejection and Tolerance.

International journal of organ transplantation medicine·2014
Same author

Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Standardization and cross validation of alloreactive IFNγ ELISPOT assays within the clinical trials in organ transplantation consortium.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

CTLA4-Ig, a costimulatory blockade agent, shows promise in inhibiting T-cell responses. It has demonstrated potential in animal models for prolonging organ survival and inducing tolerance, with early clinical trials underway for autoimmune and transplant conditions.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Pharmacology

Background:

  • T-cell activation requires antigen-specific (TCR-peptide-MHC) and antigen-nonspecific (costimulatory) signals from antigen-presenting cells (APCs).
  • The CD28/B7 interaction on APCs and T-cells is a critical costimulatory pathway; its absence leads to T-cell anergy.
  • Targeting the CD28/B7 pathway offers a strategy for immunosuppression and inducing tolerance.

Purpose of the Study:

  • To review the therapeutic potential of CTLA4-Ig (cytotoxic T-lymphocyte-associated protein 4-immunoglobulin) as a costimulatory blockade agent.
  • To summarize findings from animal models and early clinical trials regarding CTLA4-Ig's efficacy and safety.
  • To assess CTLA4-Ig's suitability for inducing donor-specific immunological tolerance in clinical immunosuppression.

Main Methods:

Related Experiment Videos

  • Review of preclinical data from various animal models investigating CTLA4-Ig's effects on immune responses.
  • Summary of early-phase clinical trial results for conditions like psoriasis and graft-versus-host disease.
  • Analysis of CTLA4-Ig's mechanism of action as a competitive inhibitor of the CD28/B7 pathway.

Main Results:

  • CTLA4-Ig demonstrated inhibition of T-cell-dependent antibody responses in animal models.
  • Significant prolongation of transplanted organ survival and induction of long-term donor-specific tolerance were observed in some models.
  • CTLA4-Ig showed immunomodulatory effects in autoimmune and other immunological disease models, entering Phase I clinical trials.

Conclusions:

  • CTLA4-Ig effectively inhibits key costimulatory pathways crucial for T-cell activation.
  • Preclinical and early clinical data suggest CTLA4-Ig is a promising agent for immunosuppression and tolerance induction.
  • Despite the absence of large randomized trials, CTLA4-Ig's specificity and low toxicity support its potential in clinical immunosuppression.